Glaukos: A Further Guidance Hike On Revenues Could Spike Shares Post Q2 ReleaseSeeking Alpha • 07/28/26
Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShuntBusiness Wire • 07/27/26
Glaukos CFO Alex Thurman Sells $1.6 Million in Stock. What Should Investors Do Now?The Motley Fool • 07/14/26
GKOS Stock Up More Than 45% Since May-End: What's Driving the Rally?Zacks Investment Research • 07/08/26
Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29Business Wire • 07/08/26
Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex BlepharitisBusiness Wire • 06/25/26
Two Medical Stocks Skyrocket After Demolishing Views — And One Is About To Break OutInvestors Business Daily • 04/30/26
Glaukos Gains on Q1 Earnings Beat & Improved 2026 Revenue OutlookZacks Investment Research • 04/30/26
Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 04/30/26
Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29Business Wire • 04/08/26